ArticleBMC medicine2025
KoMethylNet: a novel epigenetic clock based on neural network analysis of DNA methylation data and epigenetic age acceleration in a Korean population.
Article in BMC medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundEpigenetic clocks have been extensively investigated in individuals of European ancestry and may be suboptimal in East Asians. We developed a novel epigenetic clock (KoMethylNet) using neural network analysis of DNA methylation (DNAm) data from the Korean population to predict chronological ages.
methodsDNAm data (367,785 CpG sites) from 2,747 participants (Infinium Human Methylation 450 K BeadChip: N = 397; Infinium MethylationEPIC BeadChip: N = 2,350) in the Korean Genome and Epidemiology Study (KoGES) were used to train the neural network on chronological ages. SHapley Additive exPlanation analysis was used to select the optimal number of CpG sites. KoMethylNet-epigenetic age acceleration (EAA)-phenotype analysis was conducted with linear regression, to identify aging-related phenotypes in the Korean population.
resultsKoMethylNet, which uses 300 CpG sites, achieved a mean absolute error (MAE) of 2.82 years, a mean squared error (MSE) of 12.68 years, and a Pearson's correlation coefficient (R) of 0.90 with chronological age. In the external validation using healthy Korean individuals, KoMethylNet achieved the highest performance (MAE = 2.74, MSE = 12.29, R = 0.94). Seven phenotypes, including diabetes-related traits (diabetes, HbA1c, and urine glucose), were positively associated with KoMethylNet-EAA.
conclusionsWe developed a neural network-based DNAm aging clock using Korean population data that enables precise age prediction and offers potential opportunities for advancing aging-related research in Korea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.